Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

BACKGROUND: Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA. METHODS: This phase I trial was designed to determine the toxicity profile, tolerability, and recommended phase II dose of escalating doses of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Munster, P N, Marchion, D, Thomas, S, Egorin, M, Minton, S, Springett, G, Lee, J-H, Simon, G, Chiappori, A, Sullivan, D, Daud, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768109/
https://www.ncbi.nlm.nih.gov/pubmed/19738609
http://dx.doi.org/10.1038/sj.bjc.6605293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768109/
https://www.ncbi.nlm.nih.gov/pubmed/19738609
http://dx.doi.org/10.1038/sj.bjc.6605293

Ejemplares similares